{"id":24345,"date":"2022-11-15T12:39:00","date_gmt":"2022-11-15T04:39:00","guid":{"rendered":"https:\/\/flcube.com\/?p=24345"},"modified":"2025-01-31T12:43:18","modified_gmt":"2025-01-31T04:43:18","slug":"cstone-pharmaceuticals-suspends-suzhou-plant-operations-to-cut-costs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=24345","title":{"rendered":"CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs"},"content":{"rendered":"\n

CStone Pharmaceuticals (HKG: 2616<\/a>) has officially responded to recent news reports regarding the suspension of manufacturing operations at its Suzhou plant. The company stated that the decision to temporarily halt operations at the Suzhou facility is aimed at reducing operating costs, as the plant is still in the trial operation stage and there is currently no demand for mass production.<\/p>\n\n\n\n

Impact on Business Operations<\/strong>
According to CStone, its currently commercialized products are not being manufactured at the Suzhou plant. The suspension will not impact related technology transfers or other business operations, including the company’s research and development (R&D) activities and translational medicine centers in Suzhou. Core staff will be retained, and the company will actively pursue industry collaboration opportunities for the site. Additionally, CStone’s cash reserves are sufficient to support its operations for several years. The adjustment is expected to save and optimize the company’s operating costs more effectively.<\/p>\n\n\n\n

Commercialized Products and Strategic Focus<\/strong>
CStone has commercialized four products in China, including the PD-L1 inhibitor sugemalimab, which was first approved in December 2021 for the first-line treatment of metastatic non-squamous and squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy, as well as for unresectable stage III NSCLC. Other marketed products include the RET inhibitor Gavreto (pralsetinib), licensed from Blueprint Medicines; avapritinib; and ivosidenib, an IDH1 inhibitor licensed from Agios Pharmaceuticals.<\/p>\n\n\n\n

Addressing Recent Developments<\/strong>
CStone is taking steps to counter recent negative press coverage. Earlier this year, the company initiated an internal investigation into its former deputy financial president due to unauthorized investments, leading to stricter investment rules in June. In July, Bloomberg reported that CStone was exploring strategic options, including the possibility of a buyout. Additionally, its US partner EQRx Inc. (Nasdaq: EQRX) has deprioritized US development of sugemalimab, which was licensed from CStone in a 2020 deal worth up to USD 1.3 billion.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[188,2420,856,2421],"class_list":["post-24345","post","type-post","status-publish","format-standard","hentry","category-company","tag-cstone-pharmaceuticals","tag-eqrx","tag-hkg-2616","tag-nasdaq-eqrx"],"yoast_head":"\nCStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of manufacturing operations at its Suzhou plant. The company stated that the decision to temporarily halt operations at the Suzhou facility is aimed at reducing operating costs, as the plant is still in the trial operation stage and there is currently no demand for mass production.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=24345\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=24345\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-15T04:39:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-31T04:43:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24345#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24345\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs\",\"datePublished\":\"2022-11-15T04:39:00+00:00\",\"dateModified\":\"2025-01-31T04:43:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24345\"},\"wordCount\":320,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CStone Pharmaceuticals\",\"EQRx\",\"HKG: 2616\",\"NASDAQ: EQRX\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24345#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24345\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=24345\",\"name\":\"CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-11-15T04:39:00+00:00\",\"dateModified\":\"2025-01-31T04:43:18+00:00\",\"description\":\"CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of manufacturing operations at its Suzhou plant. The company stated that the decision to temporarily halt operations at the Suzhou facility is aimed at reducing operating costs, as the plant is still in the trial operation stage and there is currently no demand for mass production.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24345#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=24345\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=24345#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs - Insight, China's Pharmaceutical Industry","description":"CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of manufacturing operations at its Suzhou plant. The company stated that the decision to temporarily halt operations at the Suzhou facility is aimed at reducing operating costs, as the plant is still in the trial operation stage and there is currently no demand for mass production.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=24345","og_locale":"en_US","og_type":"article","og_title":"CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=24345","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-11-15T04:39:00+00:00","article_modified_time":"2025-01-31T04:43:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=24345#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=24345"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs","datePublished":"2022-11-15T04:39:00+00:00","dateModified":"2025-01-31T04:43:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=24345"},"wordCount":320,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CStone Pharmaceuticals","EQRx","HKG: 2616","NASDAQ: EQRX"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=24345#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=24345","url":"https:\/\/flcube.com\/?p=24345","name":"CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-11-15T04:39:00+00:00","dateModified":"2025-01-31T04:43:18+00:00","description":"CStone Pharmaceuticals (HKG: 2616) has officially responded to recent news reports regarding the suspension of manufacturing operations at its Suzhou plant. The company stated that the decision to temporarily halt operations at the Suzhou facility is aimed at reducing operating costs, as the plant is still in the trial operation stage and there is currently no demand for mass production.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=24345#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=24345"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=24345#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CStone Pharmaceuticals Suspends Suzhou Plant Operations to Cut Costs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24345","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24345"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24345\/revisions"}],"predecessor-version":[{"id":24346,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/24345\/revisions\/24346"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24345"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24345"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24345"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}